

## **CURRICULUM VITAE**

**Helene A. Emsellem, M.D.**

**PLACE OF BIRTH:** Washington, D.C.

**ADDRESS:**

**Primary Address:**

**Secondary Address**

Sleep Health Institute  
PO Box 61324  
Potomac, MD 20959  
Phone: 240-560-2230  
Fax: 1-800-886-1005

The Center for Sleep & Wake Disorders  
5454 Wisconsin Avenue, Suite 1725  
Chevy Chase, Maryland 20815  
Phone: 301-654-1575  
Fax: 301-654-5658

**PRESENT  
POSITIONS:**

July 2023 – Present  
Medical Director  
Sleep Health Institute, LLC  
PO Box 61324  
Potomac, Maryland 20859  
Phone: 240-560-2230, Fax: 1-800-886-1005

October 1995- July 2023: Owner & Director  
July 2023-present: Interim Director  
Helene A. Emsellem, MD PC  
The Center for Sleep & Wake Disorders  
5454 Wisconsin Avenue, Suite 1725  
Chevy Chase, Maryland 20815

Academic Appointment  
Clinical Professor of Neurology  
George Washington University Medical Center  
2150 Pennsylvania Avenue NW, 7<sup>th</sup> Floor  
Washington, D.C. 20037

**PREVIOUS  
POSITIONS:**

March 1992 – September 1995  
Neurologist & Sleep Lab Director  
The Neurology Center, P.A.  
5454 Wisconsin Avenue, Suite 1720  
Chevy Chase, Maryland 20815

1981 – 1992  
Tenured Associate Professor of Neurology (see appointment history page 3)  
George Washington University Medical Center  
2150 Pennsylvania Avenue NW, 7<sup>th</sup> Floor  
Washington, D.C. 20037

**EDUCATION:** 1970 – 1973  
University of Maryland  
College Park, Maryland

1977  
The George Washington School of Medicine  
Washington, D.C.

**POSTGRADUATE TRAINING:** March 1981 – July 1981  
Clinical Fellow in EEG  
Johns Hopkins Hospital, Baltimore, Maryland

1979 – 1981  
Neurology Resident,  
The George Washington University Medical Center, Washington, D.C.

July 1978 – December 1978  
Medicine Resident,  
The George Washington University Medical Center, Washington D.C.

1977 – 1978  
Psychiatry\* Intern,  
The George Washington University Medical Center, Washington, D.C.

**DIPLOMATE:** 2011 (exp. 2027)  
American Board of Psychiatry and Neurology: Sleep Medicine

1989  
American Board of Sleep Medicine

1985  
American Board of Qualification in Neurophysiology

1983 (indefinite)  
American Board of Psychiatry and Neurology

**LICENSURE:** Maryland: D0026399  
Virginia: 45761  
District of Columbia: 11220

**HONORS:** 2022  
Lifetime Achievement Award  
Maryland Sleep Society

2005  
Examiner, American Board of Psychiatry and Neurology, Inc.  
Washington, D.C.

2002  
Examiner, American Board of Psychiatry and Neurology, Inc.  
New York, New York

1991  
Dean's Commendation for Excellent Teaching

1986  
Alpha Omega Alpha (Medical Honor Society)

**CERTIFICATES:** August 2018, renewed 2023  
CITI Collaborative Institutional Training Initiative: "Basic Course & HIPAA  
and Human Subject."

December 2000  
NIH Office of Human Subjects Research: "Protection of Human Research  
Subjects."

**HOSPITAL  
PRIVILEGES:** Suburban Hospital  
Bethesda, Maryland

**ACADEMIC  
APPOINTMENTS:** July 2011 – Present  
Clinical Professor of Neurology,  
The George Washington University Medical Center, Washington, D.C.

April 1992 – July 2011  
Associate Clinical Professor of Neurology  
The George Washington University Medical Center, Washington, D.C.

September 1990 – August 1991  
Acting Chairman, Department of Neurology  
The George Washington University Medical Center, Washington, D.C.

1986 – 1992  
Associate Professor of Neurology  
The George Washington University Medical Center, Washington, D.C.

1982 – 1986  
Assistant Professor of Neurology

The George Washington University Medical Center, Washington, D.C.

1981 – 1982

Instructor of Neurology

The George Washington University Medical Center, Washington, D.C.

**Academic**

**Responsibilities:**

1985 – 1992

Director, Sleep Study Center

The George Washington University Medical Center, Washington, D.C.

1982 – 1991

Coordinator, Residency Training Program

The George Washington University Medical Center, Washington, D.C.

1981 – 1992

Director, Clinical Neurophysiology Laboratory

The George Washington University Medical Center, Washington, D.C.

**Secondary**

**Appointments:**

1992 – 1999

Associate Clinical Professor of Emergency Medicine

The George Washington University Medical Center, Washington, D.C.

1989 – 1992

Associate Professor of Emergency Medicine

The George Washington University Medical Center, Washington, D.C.

**PROFESSIONAL**

**SOCIETIES:**

American Academy of Neurology

American Academy of Sleep Medicine

Maryland Sleep Society

**ACADEMIC &**

**ADMINISTRATIVE**

**RESPONSIBILITIES:**

July 2018 – June 2019

Chairman, Board of Directors

National Sleep Foundation

2011 – 2018

Member, Board of Directors

National Sleep Foundation

2014

Chairman, National Sleep Foundation's Sleep in America Poll: Sleep in the Modern Family

2010 – Present

Member, Maryland Polysomnography Standards Committee  
Maryland Board of Physicians

2009 -- Present

Member, National Sleep Foundation Public Awareness Committee

1993

Chairman, Communications Committee  
The Neurology Center, P.A., Chevy Chase, Maryland

1992 – Present

Member, Ethics Committee  
Suburban Hospital, Bethesda, Maryland

1991 – 1992

Member, Physicians Advisory Council  
The George Washington University Medical Center, Washington, D.C.

1991 – 1992

Member, Faculty Practice Committee  
The George Washington University Medical Center, Washington, D.C.

1988 – 1992

Secretary, Alpha Omega Alpha National Medical Honor Society  
The George Washington University Medical Center, Washington, D.C.

1986 – 1992

Member, Graduate Medical Committee,  
The George Washington University Medical Center, Washington, D.C.

1984 – 1992

Member, Patient Care Committee  
The George Washington University Medical Center, Washington, D.C.

1982 – 1990

Member, Educational Planning Committee  
The George Washington University Medical Center, Washington, D.C.

1986 – 1987, 1983 – 1984

Chairperson, Third/Fourth Year Subcommittee Educational Planning Committee  
The George Washington University Medical Center, Washington, D.C.

1983 – 1984

Chairperson, Emergency Medicine Subcommittee, Educational Planning Committee

The George Washington University Medical Center, Washington, D.C.

1983 – 1984

Chairperson, Committee on Communications and Educational Resources, The George Washington University Medical Center, Washington, D.C. n

1982 – 1984

Member, Medical Faculty Senate

The George Washington University Medical Center, Washington, D.C.

## **RESEARCH**

### **GRANT SUPPORT:**

2022 – open label ongoing in 2023

Harmony Biosciences, LLC. Protocol HBS-101-CL-010: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients with Idiopathic Hypersomnia. Principal Investigator. HBS-101-CL-011 = open label extension of 010 trial.

2022-2023

Takeda Pharmaceutical Company Limited. Protocol TAK-861-1001: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK-861 in Healthy Adult and Elderly Subjects and Subjects With Narcolepsy Type 1. Principal Investigator.

2021-2023

Apnimed, Inc. Protocol MARIPOSA/APC-005: Phase 2, Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of Atomoxetine/Aroxycytynin(AD109)and Atomoxetine/Trazodone (AD504) to Atomoxetine alone or Placebo in Obstructive Sleep Apnea. Principal Investigator.

2021-2023

Vanda Pharmaceuticals, Inc. Protocol VP-VEC-162-3601: A study to evaluate the efficacy and safety of tasimelteon in treating sleep disturbances in individuals with Autism Spectrum Disorder. Principal Investigator.

2021-2023

Jazz Pharmaceuticals, Inc. Protocol JZP110-405: Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in

Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function. Principal Investigator.

2021-2023

Axsome Therapeutics, Inc. Protocol AXS-12-301: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects with Narcolepsy. Principal Investigator.

2021-2023

Axsome Therapeutics, Inc. Protocol AXS-12-302: A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects with Narcolepsy. Principal Investigator.

2021-2022

Takeda Pharmaceutical Company Limited. Protocol TAK-994-1504: A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1). Principal Investigator.

2021-2022

NLS Pharmaceuticals, Inc. Protocol NLS-1021: A Four-week, Double Blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol extended release) in Adults for the Treatment of Narcolepsy. Principal Investigator.

2021-2022

NLS Pharmaceuticals, Inc. Protocol NLS-1022: A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients with and without Cataplexy. Principal Investigator.

2021-2023

Jazz Pharmaceuticals, Inc. Protocol JZP258-401: A Phase 4 Multicenter, Open-label, Single-arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to XYWAV for the Treatment of Narcolepsy. Principal Investigator.

2021-2023

Vanda Pharmaceuticals Inc. Protocol VP-VEC-162-3502: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD). Principal Investigator.

2021-2023

Avadel Protocol CLFT218-1901: An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy. Principal Investigator.

2020-2021

Apnimed, Inc. Protocol APN-006: A Phase 2, Randomized, 3-period, Placebo-controlled, Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 versus Placebo or Atomoxetine. Principal Investigator.

2020-2021

Takeda Pharmaceutical Company Limited. Protocol TAK-994-1501: A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients with Narcolepsy Type 1. Principal Investigator.

2020-2022

Takeda Pharmaceutical Company Limited. Protocol TAK-925-2001: A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP. Principal Investigator.

2020-2021

Takeda Pharmaceutical Company Limited. Protocol TAK-925-2002: A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia. Principal Investigator.

2020-2021

Expansion Therapeutics, Inc . Protocol ERX-963-001: Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults with Myotonic Dystrophy Type 1. Principal Investigator.

2019-2020

Imbrium Therapeutics. Protocol OAG2002: A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects with an Alcohol Use Disorder who are Experiencing Insomnia Associated with Alcohol Cessation. Principal Investigator.

2019-2021

Suven Life Sciences. Protocol CTP2S13031H3: A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2mg and 4mg SUVN-G3031 Compared to Placebo in Patients with Narcolepsy with and without Cataplexy. Principal Investigator.

2019-2020

Respironics, Inc., a Philips company (“Philips Respironics”) Protocol No. SRC-SLE(PI)-CustomProgram-2018-10129: A Study to Determine Clinician and Patient Preferences Towards Interface Products Recommended by the 3D Mask Advice Tool. Principal Investigator.

2019-2020

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Protocol 401-02: Clinical Trial to Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants with Narcolepsy Type 1. Principal Investigator.

2019

Axsome Therapeutics, Inc., Protocol AXS-12-201: A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects with Cataplexy and Excessive Daytime Sleepiness in Narcolepsy. Principal Investigator.

2019-2021

Idorsia Pharmaceuticals Ltd Protocol ID-078A303: Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long-term safety and tolerability of ACT-541468 in adult and elderly subjects with insomnia disorder. Principal Investigator.

2018-2021

Jazz Pharmaceuticals Protocol JZP080-301: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension. Principal Investigator.

2018-2019

Apnimed, Inc., Protocol APN-002: Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Fixed-Dose Combinations of AD036 in Adults With Obstructive Sleep Apnea. Principal Investigator.

2018-2020

Balance Therapeutics Protocol BTB-001 IH202: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTB-001 in Adults with Idiopathic Hypersomnia. Principal Investigator.

2018-2020

Idorsia Pharmaceuticals Ltd Protocol ID-078A301: Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder. Principal Investigator.

2018-2019

Harmony Biosciences, LLC Protocol HBS-101-CL-001: An Open Label Expanded Access Program Intended to Provide Treatment with HBS-101 (Pitolisant) to Adult Patients in the U.S. with Excessive Daytime Sleepiness Associated with Narcolepsy with or without Cataplexy. Principal Investigator.

2018-2019

Respirionics, Inc., a Philips company (“Philips Respirionics”) Protocol No. SRC-AI-SleepCompanion-2018-10138: VISC-Q Trial (Validation of an Online Sleep Characterization Questionnaire). Principal Investigator.

2018

Novartis Institutes for BioMedical Research, Protocol CLML134X2201: A randomized, subject and investigator-blinded, placebo controlled, cross-over, multi-center Proof of Concept (PoC) study to assess the wakefulness promoting effect, safety, tolerability, and pharmacokinetics of LML134 in shift work disorder (SWD) patients. Principal Investigator.

2018

Eisai Inc. Protocol E2006-A001-102 : A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects with Mild Obstructive Sleep Apnea. Principal Investigator.

2017 – 2019

Jazz Pharmaceuticals. Protocol 15-006: “A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy.” Principal Investigator.

2017 - 2019

Flamel Ireland Ltd trading under the business name Avadel Ireland. Protocol CLFT218-1501: “Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy.” Principal Investigator.

2017 – 2018

Night Balance, B.V. Protocol US-2017-001: “The POSAtive Study: A Prospective, Randomized, Crossover Study of the NightBalance Sleep Position Trainer (SPT) Compared to Automatic Adjusting Positive Airway Pressure (APAP) for the Treatment of Positional Obstructive Sleep Apnea (POSA).” Principal Investigator.

2017 – 2018

Vanda Pharmaceuticals, Inc. VP-VEC-162-3107: “The Jet8 Study: A double-blind, placebo-controlled, study to investigate tasimelteon in healthy sleeping subjects with jet-lag type insomnia induced by an 8-hour phase advance.” Principal Investigator.

2017 - 2018

Jazz Pharmaceuticals, Protocol 166-201: “A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in Subjects with Parkinson’s Disease and Excessive Sleepiness.” Principal Investigator.

2017

Philips Respironics, Protocol AI-16128-PSPIV-LO: “A Double-blind, Placebo-controlled, Multisite, Randomized Crossover Study of the Effectiveness and Efficacy of the Power Sleep Device.” Principal Investigator.

2016 – 2018

Vanda Pharmaceuticals. Protocol VP-CEV-162-2102 "A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Proof of Concept Study to Evaluate the Effects of Multiple Oral Doses of Tasimelteon and Matching Placebo in Travelers with Jet Lag Disorder." Principal Investigator.

2016 – 2017

Merck Sharp & Dohme Corp. Protocol MK-4305-061-00 "A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease." Principal Investigator.

2016 – 2017

Eisai Inc. Protocol E2006-G000-304 "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older with Insomnia Disorder." Principal Investigator.

2016 – 2017

Audiodontics, LLC. Protocol Accession Number: 3684225 “System for Monitoring Dental Device Compliance and Efficacy in Treatment of Obstructive Sleep Apnea” Sub-Investigator.

2015 – 2017

Balance Therapeutics, Protocol BTD-001 IH201: “A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults with Idiopathic Hypersomnia or Narcolepsy Type 2.” Principal Investigator.

2015 – 2021

Vanda Pharmaceuticals, Protocol VP-VEC-162-2401: “A Double-blind, Randomized, Two-period Crossover Study Evaluating the Effects of 20 mg Tasimelteon vs. Placebo on Sleep Disturbances of Individuals with Smith-Magenis Syndrome (SMS).” Principal Investigator.

2015 – 2018

Vanda Pharmaceuticals, Protocol VP-VEC-162-0101: “An Observational Study to Investigate the Effects of Rapid Transmeridian Travel Across 5 and 8 Time Zones.” Principal Investigator.

2015 – 2017

Jazz Pharmaceuticals, Protocol 14-002: “A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy.” Principal Investigator.

2015 - 2017

Jazz Pharmaceuticals, Protocol 14-003: “A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Obstructive Sleep Apnea (OSA).” Principal Investigator.

2015 - 2017

Jazz Pharmaceuticals, Protocol 14-005: “A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea.” Principal Investigator.

2013 – 2017

Apnicure, Inc. Protocol 11847: “A Multicenter, Prospective, Variable Duration, Reiterative Development and Evaluation Study of ApniCure's Therapy System(s) for the Treatment of Obstructive Sleep Apnea.” Principal Investigator.

2012 – 2013

UCB Biosciences, Inc. Protocol RL0003: “A Phase 3B, double-blind, randomized, placebo-controlled study of Rotigotine and its effect on all-day functioning and quality of life in subjects with moderate to severe idiopathic Restless Legs Syndrome.” Principal Investigator.

2012-2013

Aerial BioPharma, LLC. Protocol ADX-N05 202: “A twelve-week, double-blind, placebo-controlled, randomized, parallel-group, multi-center study of the safety and efficacy of ADX-N05 in the treatment of excessive daytime sleepiness in subjects with narcolepsy.” Principal Investigator.

2012-2013

The GlaxoSmithKline group of companies Study. Protocol RXP114025: “A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects with Moderate-to-Severe Primary Restless Legs Syndrome (RLS).” Principal Investigator.

2012-2013

Novo Nordisk. Protocol NN8022-3970 SCALE – Sleep Apnea: “Effect of Liraglutide in Obese Subjects with Moderate or Severe Obstructive Sleep Apnea. A 32 week randomized, double-blind, placebo-controlled, parallel group, multi-center and multinational trial.” Principal Investigator.

2011 – 2012

Aerial BioPharma, LLC. Protocol ADX-N05 201: “A four-week, double-blind, placebo-controlled, randomized, cross-over study of the safety and efficacy of ADX-N05 in the treatment of excessive daytime sleepiness.” Principal Investigator.

2011 – 2015

Vanda, Inc. Protocol VP-VEC-162-3204: “An Extension Open-Label Safety Study of a 24-Month 20 mg Dose Regimen of Tasimelteon for the Treatment of N24HSWD in Blind Individuals with No Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials.” Principal Investigator.

2011 – 2012

Neurim Pharmaceuticals (1991), Ltd. Protocol No. NEU-P11-03-PSG: “A Double-blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of Neu-P11 in Insomnia Patients Aged 18-80.” Principal Investigator.

2011 – 2013

Apnex Medical, Inc. Medical Study Number CLP-005: “Pivotal Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea.” Principal Investigator.

2011 – 2013

Vanda, Inc. Protocol VP-VEC-162-3203: “A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD.” Principal Investigator.

2010 – 2012

Vanda, Inc. Protocol VP-VEC-162-3201: “A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects with N24HSWD Followed by an OLE Phase.” Principal Investigator.

2010 – 2011

Pfizer, Inc. Protocol A0081185: “A Randomized Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study of Pregabalin and Pramipexole in Adults with Restless Legs Syndrome.” Principal Investigator.

2010 – 2011

Merck & Co., Inc. Protocol #028-00: “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia.” Principal Investigator.

2010

Cephalon, Inc. Protocol #C10953/4030. “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder.” Principal Investigator.

2010

Sepracor. Protocol #190-247: “A Long-Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention- Deficit/Hyperactivity Disorder-Associated Insomnia.” Principal Investigator.

2009 – 2011

Pfizer, Inc. Protocol A0081186: “Randomized, Double-Blind, 12-Month Study of Pregabalin in Subjects with Restless Legs Syndrome.” Principal Investigator.

2009 – 2010

Cephalon, Inc. Protocol #C10953/3069/ES/MN: “A 12-Month Open-Label Study to Evaluate the Safety, Tolerability, and Efficiency of Armodafinil (150 and 250 mg/day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury.” Principal Investigator.

2009 – 2010

Cephalon, Inc. Protocol # C10953/3067/ES/MN: “A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (50, 150, and 250 mg/day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury.” Principal Investigator.

2008 – 2009

Sanofi-Aventis U.S., Inc. Protocol #EFC10844: “Efficacy and Safety of Eplivanserin 5mg/day in Insomnia Characterized by Sleep Maintenance Difficulties: A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography study.” Principal Investigator.

2008 – 2009

GlaxoSmithKline. Study RXP11098: “A Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep disturbance.” Principal Investigator.

2008 – 2009

Eli Lilly and Company. Protocol #12K-MC-ZZAD: “A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients with Insomnia.” Primary Investigator.

2008

Merck & Co., Inc. Protocol #015-02: “A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate the Safety and Efficacy of MK-0249 in Treating Refractory Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy.” Principal Investigator.

2008

Arena Pharmaceuticals, Inc. Protocol #APD125-007: “A Randomized, Double-Blind, Placebo Controlled Subjective Study to Assess the Efficacy of APD125 in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep.” Principal Investigator.

2008

Pfizer, Inc. Protocol #A4251033: “PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter

Outpatient Trial of PD 0200390 in Adults with Nonrestorative Sleep.” Principal Investigator

2007 – 2008

Pfizer, Inc. Protocol #A4251037. “PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of PD 0200390 in Adults with Primary Insomnia.” Principal Investigator

2007 – 2008

Cephalon, Inc. Protocol #C10953/4024/ES/US: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Armodafinil at a Target Dosage of 200 mg/day as Treatment for Adults with Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea/Hypopnea Syndrome with Comorbid Major Depressive Disorder or Dysthymic Disorder.” Principal Investigator.

2007 – 2008

Organon. Protocol #176002 “A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial with Org 50081 in Patients with Chronic Primary Insomnia.” Principal Investigator.

2007

Vanda Pharmaceuticals, Inc. VP-VEC-162-3104 “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/day and 50 mg/day) in the Treatment of Primary Insomnia.” Principal Investigator.

2007

Takeda Inc. Protocol #01-04-TL-375-044: “A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals with Delayed Sleep Phase Syndrome (DSPS).” Principal Investigator.

2007

Takeda Inc. Protocol #01-06-TL-375-071: “Randomized, Double-Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien®)  $\geq$  mg Therapy in Subjects with Chronic Insomnia.” Principal Investigator.

2007

Sanofi Aventis. Protocol #EFC6072: “Efficacy and Safety of 2mg/day M100907 on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study.” Principal Investigator.

2007

Organon. Protocol #176004: “Fifty-Two Weeks, Open-Label Extension Trial to Evaluate the Safety and Efficacy of Org 50081 in Outpatients with Chronic Primary Insomnia who Completed Clinical Trial Protocol 176001 or 176002.” Principal Investigator.

2006 – 2007

Arena Pharmaceuticals, Inc. Protocol #APD 125-004: “A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate Effects of APD125 in Patients with Insomnia.” Principal Investigator.

2006 – 2007

Neurogen Corporation. Protocol #NG2-73-203: “A Multi-Center, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of Two Weeks of Dosing of Various Formulations and Doses of NG2-73 and Placebo for Sleep Initiation in Primary Insomniacs.” Principal Investigator.

2006 – 2007

Sanofi Aventis. Protocol #EFC6220: “Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.” Principal Investigator.

2006 – 2007

Schwarz Biosciences Inc. Protocol #SP793: “An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal Rotigotine in Subjects with Idiopathic Restless Leg Syndrome.” Principal Investigator.

2006

Sanofi Aventis. Protocol #LTE6262: “Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: a 12-Week Multicenter, Randomized, double-Blind, Placebo-Controlled Study Followed by an Open Treatment Phase Extension with Eplivanserin for 40 Weeks Period.” Principal Investigator.

2006

Vanda Pharmaceuticals Inc. Protocol #VP-VEC-162-3101: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of a Single Oral Dose Of VEC-162 (20, 50, And 100 mg) and Matching Placebo in Healthy Male and Female Subjects with Induced Transient Insomnia.” Principal Investigator.

2006

GlaxoSmithKline. Protocol #MAD105514: “A Randomized, Double-Blind, Cross-Over Study to Evaluate the Effects Of GW679769 (2.5, 10 And 30 mg) on PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia.” Principal Investigator.

2006

Takeda, Inc. Protocol #01-05-TL-375-055: “A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Proof-Of-Concept Study to Evaluate the Safety and Efficacy of Rozerem™ Taken in Combination with Gabapentin for the Treatments of Subjects with Chronic Insomnia.” Principal Investigator.

2005 – 2007

Takeda, Inc. Protocol #TAK-375 EC302: “A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Long-Term Efficacy and Safety of Ramelteon in Adults with Chronic Insomnia.” Principal Investigator.

2005 – 2007

Schwarz Biosciences Inc. Protocol #SP792: “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects with Idiopathic Restless Leg Syndrome.” Principal Investigator

2005 – 2006

Cephalon, Inc. Protocol #C10953/3046/ES/US: “A Short-Term (8-Week) Open-Label Study, Followed by a Long-Term Evaluation, to Assess Patient-Reported Outcomes with Armodafinil Treatment (150 to 250 mg/day) for Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.” Principal Investigator.

2005 – 2006

Cephalon, Inc. Protocol #C10953/3045/CM/US: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL (200 mg) in Patients with Chronic Shift Work Sleep Disorder.” Principal Investigator.

2005

Neurocrine Biosciences, Inc. Protocol #NBI-34060-0501: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Primary Insomnia Patients with Sleep Maintenance Difficulties.” Principal Investigator.

2005

Takeda, Inc. Protocol #01-02-TL-375-018: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Phase Shifting Effects of Repeated Daily Dosing of Ramelteon in Healthy Subjects.” Principal Investigator.

2005

Takeda, Inc. Protocol #01-04-TL-375-041: “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon (TAK-375) in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data.” Principal Investigator.

2004 – 2007

Merck & Co., Inc. Protocol #20041265: “A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-night Polysomnographic Study of MD-0928 in Elderly Patients with Primary Insomnia.” Principal Investigator.

2004 – 2006

Merck & Co., Inc. Protocol #20041255: “A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-night Polysomnographic Study of MD-0928 in Adult Patients with Primary Insomnia.” Principal Investigator.

2004 – 2006

Sanofi-Synthelabo. Protocol #CPR-LTE5407-ENE01: “Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5-mg Compared to Placebo, When Both are Administered Over a Long-Term Period “As Needed”, in Patients With Chronic Primary Insomnia (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study.” Principal Investigator.

2004 – 2006

Cephalon, Inc. Protocol #C10953/3024/ES/MN: “A 12-Month, Open-Label, Flexible-Dosage (100-250 mg/day) Extension Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol # C1538/3029/ES/MN: “A 1-Year Open-Label, Flexible-Dosage Extension Study to Assess the Efficacy and Safety of PROVIGIL® (Modafinil) Treatment (100,200, and 400 mg/day) in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol # C1538/3028/AP/MN: “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of PROVIGIL® (Modafinil) Treatment (100,200, and 400 mg/day) in Children and Adolescents with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol # C1538/3027/NA/MN: “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of PROVIGIL® (Modafinil) Treatment (100,200, and 400 mg/day) in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol #C10953/3022/CM/MN: “A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg) as Treatment for Adults with Excessive Sleepiness Associated with Chronic Shift Work Sleep Disorder.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol #C10953/3020/NA/MN: “A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP--10953 (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy.” Principal Investigator.

2004 – 2005

BoehringerIngelheim Pharmaceuticals Inc. Protocol: Restless Legs Syndrome Trial 248.543: “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg of Pramipexole (Mirapex) Administered Orally to Investigate the Safety and Efficacy in Patients with Idiopathic Restless Legs Syndrome for 12 Weeks.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol #C6671/2021/IN/US: “A 12 Month, Open-Label Study to Evaluate the Safety and Efficacy of GABITRIL at Dosages up to 8 mg/day in Elderly Adults with Primary Insomnia.” Principal Investigator.

2004 – 2005

Cephalon, Inc. Protocol #C6671/2020/IN/US: “A 12-Month, Open-Label Study to Evaluate the Safety and Efficacy of GABITRIL at Doses up to 10 mg/day in Adults with Primary Insomnia.” Principal Investigator.

2004

Cephalon, Inc. Protocol #C6671a/206/IN/US: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of GABITRIL (4, 6, 8, and 10 mg) Treatment in Adult Patients with Primary Insomnia.” Principal Investigator.

2004

Cephalon, Inc. Protocol #C6671a/207/IN/US: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of GABITRIL (2, 4, 6, and 8 mg) Treatment in Elderly Patients with Primary Insomnia.” Principal Investigator.

2003 – 2004

Orphan Medical. Protocol #OMC-SXB-22: “Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil with Placebo in the Treatment of Daytime Sleepiness in Narcolepsy.” Principal Investigator.

2002 – 2004

Neurocrine Biosciences. Protocol #NBI-34060-MR-0220: “A Phase III, Open-Label Outpatient Extension Study to Assess the Long-Term Safety of a Modified Release Formulation of NBI-34060 in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties.” Principal Investigator.

2002 – 2003

Neurocrine Biosciences. Protocol #NBI-34060-MR-0212: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients With Sleep Maintenance Difficulties.” Principal Investigator.

2002 – 2003

Neurocrine Biosciences. Protocol #NBI-34060-MR-0221: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Adult Primary Insomnia Patients With Sleep Maintenance Difficulties.” Principal Investigator.

2002 – 2003

Neurocrine Biosciences. Protocol #NBI-34060-IR-0114: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of NBI-34060 in Adults with Primary Insomnia.” Principal Investigator.

2002 – 2003

Takeda Pharmaceuticals North America, Inc. Protocol #01-02-TL-375-021: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, PSG plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults with Chronic Insomnia.” Principal Investigator.

2002 – 2003

Takeda Pharmaceuticals North America, Inc. Protocol #01-02-TL-375-022: “A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long Term Administration of TAK-375 in Subjects with Chronic Insomnia.” Principal Investigator.

2002 – 2003

Takeda Pharmaceuticals North America, Inc. Protocol #01-02-TL-375-023: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia.” Principal Investigator.

2002 – 2003

Orphan Medical. Protocol #OMC-SXB-19: “Open-Label, Multi-Center Safety Trial Studying the Effects of Orally Administered Xyrem (Sodium Oxybate).” Principal Investigator.

2002 – 2003

Orphan Medical. Protocol #OMC-SXB-15: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) with Placebo for the Treatment of Narcolepsy.” Principal Investigator.

2002 – 2003

Sanofi-Synthelabo Research. Protocol #EFC4529: “Comparison of Efficacy and Safety of Zolpidem-MR 12.5mg and Placebo in Patients with Primary Insomnia. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study.” Principal Investigator.

2001 – 2003

Cephalon, Inc. Protocol #C1538a/306/CM/US-UK: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Impact on Quality of Life of 12 Weeks of PROVIGIL (Modafanil) Therapy at Dosages of 200 and 300mg Once Daily as Treatment for Adults With Excessive Sleepiness Associated With Shift Work Sleep Disorder, Followed by a 12-Month Open-Label Extension Period.” Principal Investigator

2001 – 2002

Sepracor. Protocol #190-047: “A Randomized, Double-Blind, Placebo-Controlled, Parallel, Two-Week, Objective Efficacy and Safety of Eszopiclone in Elderly Subjects with Primary Insomnia.” Principal Investigator

2000 – 2003

Orphan Medical. Protocol #OMC-SXB-21: “Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Assess the Long-Term Efficacy of Orally Administered Xyrem (Sodium Oxybate) when Compared to Placebo.” Principal Investigator

2000 – 2001

Sepracor. Protocol #190-046: “A Double-Blind, Placebo-Controlled Parallel Randomized Study of the Efficacy and Safety of (S)-Zopiclone in the Treatment of Adult Subjects with Primary Insomnia.” Principal Investigator

2000 – 2001

Sanofi-Synthelabo. Protocol #DRI3210 and #LTS3698: “Double-Blind Placebo Controlled Study of the Efficacy and Safety of Three Doses of SR46349B in Patients with Obstructive Sleep Apnea Hypopnea Syndrome.” Principal Investigator

1998 – 2003

Orphan Medical. Protocol #OMC-SXB-7: “Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy.” Principal Investigator.

1998 – 2000

Orphan Medical. Protocol #OMC-SXB-6: “Open-Label, Multi-Center, Six-Month Trial of Xyrem (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy in Study Drug Naive Patients.” Principal Investigator

1998 – 1999

Cephalon, Inc. Protocol. “A Four-Week Double Blind, Placebo Controlled, Multicenter, Randomized, Parallel Group Study of the Effect of Provigil (Modafinil) on Excessive Daytime Sleepiness and Vigilance in Obstructive Sleep Apnea in Patients Treated with Nasal Continuous Positive Airway Pressure.” Principal Investigator.

1998

Cephalon Pilot Protocol. “Survey of Patient’s Willingness to Pay.” Principal Investigator.

1997 – 1998

Orphan Medical. Protocol #OMC-GHB-3: “Long-Term, Open-Label, Multi-Center Extension Trial of Orally Administered Xyrem (gamma-hydroxybutyrate) for the Treatment of Narcolepsy Symptoms.” Principal Investigator.

1997 – 1998

Orphan Medical. Protocol #OMC-GHB-2: “Placebo Controlled Double Blind Study of the Safety and Efficacy of Gamma Hydroxy Butyrate in Patients with Cataplexy.” Principal Investigator

1996 – 1998

International Clinical Research Corporation: Cephalon, Inc. Protocol #C1538a/301: “Open Label, Continued Open Label, Extended Open Label. ‘Study of the Safety and Efficacy of Oral Modafinil in Patients with Narcolepsy.’” Principal Investigator.

1994 – 1996

International Clinical Research Corporation: Cephalon, Inc. Protocol #C1538a/301: “Placebo Controlled Double Blind Study of the Safety and Efficacy of Oral Modafinil in Patients with Narcolepsy.” Principal Investigator.

1990

Research Foundation of the American Society of Colon and Rectal Surgeons. "Anorectal Motility and the Rectal Complex during Sleep." Co-investigator with Bruce Orkin, MD.

1990

Neuromedical Technologies, Inc. "The Effects of Transcranial Electrostimulation Therapy on Sleep in Normal Subjects." Principal Investigator.

1988-89

Edentech Biomedical. "The Verification of the Sensitivity and Diagnostic Accuracy of a Portable Apnea Screening Device." Principal Investigator.

1986-87

The George Washington University Research Grant. "Brain Electrical Activity Mapping (BEAM) of Visual Evoked Potentials Recorded During the Performance of Verbal and Nonverbal Tasks." Co-investigator with Craig Linebaugh, PhD, Professor, Department of Speech and Hearing, GWUMC.

## **RESEARCH PROTOCOLS**

### **(UNSUPPORTED):**

1990 – 1991

Psychophysiological Response Patterns in Psychiatric Patients and Normal Volunteers

1991 – 1992

Establishment of Normative Data Pudental EPs

1989 – 1990

The Evaluation of Apnea in Children Who Snore

1989 – 1990

Continuous Attention Tasks in Narcolepsy

1988 – 1990

The Establishment of Normative Control Data for Rectal Evoked Potentials

1986 – 1987

The Effect of Anesthesia on Somatosensory Responses

1986 – 1987

The Establishment of Normative Control Data for Pudental Evoked Potentials

**JOURNAL  
ARTICLES:**

Aleksandar Videnovic, MD; Amy W. Amara, MD, PhD; Cynthia Comella, MD; Paula K. Schweitzer, PhD; Helene Emsellem, MD; Kris Liu, PhD; Amanda L. Sterkel, PhD; Mildred D. Gottwald, PharmD; Joshua R. Steiner, MD; Philip Jochelson, MD; Katie Zomorodi, PhD; Robert A. Hauser, MD, MBA.

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. In Review *Movement Disorders Journal*. 2021.

Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. *Sleep Med* 67:128-136. December 2019.

Berry RB, Uhles ML, Abaluck BK, Winslow DH, Schweitzer PK, Gaskins RA Jr, Doekel RC Jr, Emsellem HA. NightBalance Sleep Position Treatment Device Versus Auto-Adjusting Positive Airway Pressure for Treatment of Positional Obstructive Sleep Apnea. *J Clin Sleep Med* 15(7):947-956. July 2019.

Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. *Am J Respir Crit Care Med* 199(11):1421-1431. June 2019.

Emsellem, H. The reimagining of sleep health. *Sleep Health: Journal of the National Sleep Foundation*. *Sleep Health* 5 (2019) 2. February 2019.

Thorpy M, Shapiro C, Mayer G, Corser B, Emsellem H, Plazzi G, Chen D, Carter L, Wang H, Lu Y, Black J, Dauvilliers Y. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. *Annals of Neurology* 85(3). March 2019.

Emsellem, H. Explore Sleep Health Under One Roof. *Sleep Health: Journal of the National Sleep Foundation*. *Sleep Health* 4 (2018) 499. December 2018.

Emsellem, H. Annual State of Sleep Health Address from the National Sleep Foundation Chairman. *Sleep Health: Journal of the National Sleep Foundation*. *Sleep Health* 4 (2018) 316. August 2018.

Scrima L, Emsellem HA, Becker PM, Ruoff C, Lankford A, Bream G, Khayrallah M, Lu Y, Black J. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110. *Sleep Med* 38:108-112. October 2017. Epub July 2017.

Erman M, Emsellem H, Black J, Mori F, Mayer G. Correlation between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in patients with narcolepsy participating in two clinical trials of sodium oxybate. *Sleep Medicine*. 2017;38:92–95.

Ruoff C, Bogan RK, Emsellem H, Feldman N, Bream G, Khayrallah M, Lu Y, Carter LP. Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes. *Sleep Medicine* 35:12-16. 2017.

Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, Bream G, Khayrallah MA, Lu Y, Black J. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study. *Sleep* 39(7):1379-87. July 2016.

Khanijow V, Prakash P, Emsellem HA, Borum ML, Doman DB. Sleep Dysfunction and Gastrointestinal Diseases. *Gastroenterol Hepatol (N Y)* 11(12):817-25. December 2015.

Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford DA. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. *Sleep Med* 16(9):1102-8. September 2015. Epub June 2015.

Mamelak M, Swick T, Emsellem H, Montplaisir J, Lai C, Black J. A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy. *Sleep Med* 16(1):52-8. January 2015. Epub October 2014.

Bogan R, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford A. Effect of Oral JZP-110 (ADX-N05) Treatment on Wakefulness and Sleepiness in Adults With Narcolepsy. *Sleep Medicine* February 2015.

Buxton O, Chang AM, Spilsbury JC, Bos T, Emsellem H, Knutson KL. Sleep in the Modern Family: Protective Family Routines for Child and Adolescent Sleep. *Sleep Health* 2015; 1(1) 15-27.

Merikangas KR, Zhang J, Emsellem H, Swanson SA, Vgnotzas A, Beloud F, Blank MM, Chen W, Einen MD, He JP, Heaton E, Nakamura E, Rooholamini S, Mignot E. Structured Diagnostic Interview for Sleep

Patterns and Disorders: Rationale and Validity. *Sleep Medicine* 2014; 15(5): 530-535.

U.S. Xyrem Multicenter Study Group. Sodium Oxybate is Effective for the Treatment of Excessive Daytime Somnolence in Narcolepsy. *J Clin Sleep Med* 1(4) 391-397. 2005.

U.S. Xyrem Multicenter Study Group: A Double-Blind, Placebo-Controlled Study Demonstrates Sodium Oxybate is effective for the Treatment of Excessive Daytime Sleepiness in Narcolepsy. *J Clin Sleep Med* 1(4) 391-397. 2005.

U.S. Xyrem Multicenter Study Group: Further Evidence Supporting the Use of Sodium Oxybate for the Treatment of Cataplexy: A Double-Blind, Placebo-Controlled Study in 228 Patients. *Sleep Medicine* 6(5) 415-421. 2005.

U.S. Xyrem Multicenter Study Group: Sodium Oxybate Demonstrates Long-term Efficacy for the Treatment of Cataplexy Associated with Narcolepsy. *Sleep Medicine* 5 (2004) 119 – 123.

U.S. Xyrem Multicenter Study Group: A 12-Month, Open-Label, Multicenter Extension Trial of Orally Administered Sodium Oxybate for the Treatment of Narcolepsy. *SLEEP* 26(1), 2003.

U.S. Xyrem Multicenter Study Group: The Abrupt Cessation of Therapeutically Administered Sodium Oxybate (GHB) Does Not Cause Withdrawal Symptoms. *SLEEP* 41(2): 131 – 135, 2003.

U.S. Xyrem Multicenter Study Group: A Randomized, Double-Blind, Multicenter Trial Comparing the Effects of Three Doses of Orally Administered Sodium Oxybate with Placebo for the Treatment of Narcolepsy. *SLEEP* 25(1): 42 – 49, Feb 2002.

U.S. Modafinil in Narcolepsy Multicenter Study Group: Long-term Efficacy and Safety of Modafinil (PROVIGIL) for the Treatment of Excessive Daytime Associated with Narcolepsy. *Sleep Medicine* 1: 231 – 243, 2000.

Pack, Allan, U.S. Modafinil in Obstructive Sleep Apnea Study Group: Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea. *American Journal of Respiratory Critical Care Medicine* 164: 1675 – 1681, 2001.

Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L, Goswami M, Steinwald B: Health-Related Quality of Life Effects of Modafinil for Treatment of Narcolepsy. *Sleep* 22(6): 757 – 765, 1999.

Modafinil Study Group: Randomized Trial of Modafinil for the Treatment of Pathological Somnolence in Narcolepsy. *Ann Neurol* 43(1): 88 – 97, 1998.

Hyde TM, Emsellem HA, Rickler KC, Weinberger DR:  
Electroencephalographic Abnormalities in Monozygotic Twins with Tourette's Syndrome. *Br J Psychiatry* 164(6): 811 – 817, 1994.

DePalma RG, Dalton CM, Gomez CA, McNellis RJ, Schwab FO, Miller HC, Emsellem HA: Predictive Value of a Screening Sequence for Venogenic Impotence. *Int. J. Impotence. Res* 4, 143 – 148, 1992.

Emsellem, HA and Rappaport, BA: Periodic Leg Movements of Sleep and the Restless Leg Syndrome. Report of the National Commission on Sleep Disorders Research. Submitted to Congress February 1992.

Emsellem, HA, Corson, WA, Rappaport, BA et al: Verification of a Portable Sleep Apnea Screening Device. *Southern Medical Journal* 83(7): 748 – 752, 1990.

Katz LM, Emsellem HA, Borenstein DG: Evaluation of Cervical Spine Inflammatory Arthritis with Somatosensory Evoked Potentials (SEPs). *Journal of Rheumatology*, 17(4): 508 – 514, 1990.

Rappaport B, Emsellem HA, Shesser R: An Unusual Case of Proctalgia. *Annals of Emergency Medicine* 19(2): 201 – 203, 1990.

DePalma RG, Schwab F, Drury EM, Miller HC, Emsellem HA, Edwards CM, and Bergsrud D: Experience in Diagnosis and Treatment of Impotence Due to Cavernal Leak Syndrome. *Journal of Vascular Surgery* 10(2): 117 – 121, 1989.

DePalma RG, Emsellem HA, Edwards CM, et al: A Screening Sequence for Vasculogenic Impotence. *Journal of Vascular Surgery* 5(2): 228 – 236, 1987.

Emsellem HA: Metastatic Disease of the Spine: Diagnosis and Management. *Southern Medical Journal* 79(11): 1405 – 1412, 1986.

Rosenthal R, Emsellem HA, Kline P: Truncal Seizures: An Unusual Presentation of Cerebral Cysticercosis. *Annals of Emergency Medicine* 15: 1360 – 1362, 1986.

Emsellem HA: *NeuroLogic*, 1985. Copyright 1985. (A clinical neurology teaching text).

Morgan SA, Emsellem HA, Sandler JR: Absence of the Septum Pellucidum: Overlapping Clinical Syndromes. *Archives of Neurology* 42: 769 – 770, 1985.

Kantor HL, Emsellem HA, Hogg JE, Simon GL: *Candida Albicans* Meningitis in a Parenteral Drug Abuser. *Southern Medical Journal* 77: 404 – 405, 1984.

## ABSTRACTS

Dauvilliers Y, Shapiro C, Mayer G, Lammers GL, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Thorpy MJ: Solriamfetol (JZP-110) for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy with and without cataplexy: results of a randomized phase 3 clinical trial. Accepted for Presentation at JNFL 2020, Lyon, France. April 2020.

Rosenberg R, Thorpy MJ, Emsellem H, Schweitzer PK, Chen D, Baladi M, Babson K, Liu K, Shapiro C.: Pooled Analysis From 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment of Excessive Daytime Sleepiness in Participants With Obstructive Sleep Apnea or Narcolepsy. Presented at the Psych Congress 2019 meeting, San Diego, California. October 2019.

Black J, Dauvilliers Y, Plazzi G, Shapiro CM, Mayer G, Corser BC, Emsellem H, Chen D, Carter LP, Wang H, Thorpy MJ: Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2. Submitted to Birmingham Sleep (BSS) 2019.

Mayer G, Dauvilliers Y, Shapiro CM, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Black J, Thorpy M: Randomised, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants With Narcolepsy Types 1 and 2. Submitted to the Die Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM). June 2019.

Thorpy MJ, Emsellem H, Rosenberg R, Schweitzer PK, Chen D, Baladi M, Babson K, Liu K, Shapiro C: Pooled analyses from 12-week randomized, controlled studies of solriamfetol in the treatment of excessive daytime sleepiness in participants with OSA or narcolepsy. Presented at the 31st Annual Meeting of the Associated Professional Sleep Societies, LLC. June 2019.

Shapiro, C, Emsellem H, Rosenberg R, Schweitzer PK, Chen D, Baladi M, Babson, K, Liu K, Thorpy, MJ: Solriamfetol for excessive daytime sleepiness in narcolepsy or OSA: pooled analyses of 12-week, randomized, controlled studies by demographic factors. Presented at the American Psychiatric Association Annual Meeting, San Francisco, California. May 2019.

Emsellem, H, Thorpy MJ, Lammers, GJ, Shapiro, C, Mayer, G, Plazzi, G, Chen, D, Carter, LP, Ryan, R, Black, J, Dauvilliers, Y: Quality of Life, Functional

Evaluation, and Work Productivity in Patients With Narcolepsy: Results From a Phase 3 Study of Solriamfetol (JZP-110). Presented at the 24<sup>th</sup> Congress of the European Sleep Research Society (ESRS), Basel, Switzerland. September 2018.

Thorpy MJ, Shapiro C, Mayer G, Corser BC, Chen D, Li J, Carter LP, Wang H, Black J, Emsellem H, Plazzi G, Dauvilliers Y: A Randomized, Placebo-Controlled, Phase 3 Study of Solriamfetol (JZP-110) in Patients With Narcolepsy: Effects on Wakefulness, Excessive Sleepiness, and Health-Related Quality-of-Life. Presented at the 56<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, December 2017.

Thorpy MJ, Dauvilliers Y, Shapiro C, Mayer G, Corser BC, Chen D, Li J, Carter LP, Wang H, Lu Y, Black J, Emsellem H: A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of JZP-110 for the Treatment of Excessive Sleepiness in Patients with Narcolepsy. Presented at the 31st Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2017.

Erman, M, Emsellem, H, Black, J, Mori, F, Mayer, G: Correlation Between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in Patients with Narcolepsy Participating in Two Clinical Trials of Sodium Oxybate. Presented at the 23<sup>rd</sup> Congress of the European Sleep Research Society, Bologna, Italy, September 2016.

Ruoff, C, Bogan, R, Emsellem, H, Feldman, N, Lankford, A, Bream, G, Khayrallah, M, Lu, Y, Black, J. JZP-110 Has a Large Effect Size on the Maintenance of Wakefulness Test in Patients With Narcolepsy Independent of 20- or 40- Minute Censorship of the Data. Presented at the 23<sup>rd</sup> Congress of the European Sleep Research Society, Bologna, Italy, September 2016.

Scima, L, Emsellem, H, Becker, P, Ruoff, C, Lankford, A, Bream, G, Khayrallah, M, Black, J: Definition of a Responder to Narcolepsy Treatment Based on the Results of a Clinical Trial of JZP-110. Presented at the 29<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2015.

Scima, L, Emsellem, H, Becker, P, Ruoff, C, Lankford, A, Bream, G, Khayrallah, M, Black, J: Patient Global Impression of Change Correlates with Clinical Global Impression of Change in a Clinical Trial of JZP-110 for the Treatment of Narcolepsy. Presented at the 29<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2015.

Reich, D, Emsellem, HA: Presence of Mandibular Tori as a Diagnostic Precursor to Obstructive Sleep Apnea. Presented at the 29<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2015.

Buxton, O, Chang, A, Spilsbury, J, Bos, T, Emsellem, HA, Knutson, K: Sleep in the Modern Family: Protective Family Routines for Child and Adolescent Sleep: Results from the 2014 Sleep in America Poll. Presented at the 29<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2015.

Bos, T, Low, A, Emsellem, HA: Improving APAP Compliance: The Importance of Individualized Pressure Ranges and Early Follow-up. Presented at the 29<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2015.

Mamelak, M, Swick, T, Emsellem, HA, Montplaisir, J, Lai, C, Black, J: A 12-Week Open-Label, Multicenter Study Evaluating Sodium Oxybate (SXB) in Patient With Narcolepsy. Presented at the 2014 Annual Meeting of the American Neurological Association, October 2014.

Wentworth, C, Bos, T, Emsellem, HA: Subjective Analogue Sleepiness Scale as a Predictor of Abnormal Multiple Sleep Latency Test. Presented at the 28<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2014.

Emsellem, HA, Winslow, DH, Siegel, LC, Bogan, RK, McCullough, PA, Stiles J: Safety and Effectiveness of Oral Pressure Therapy with a New Oral Interface. Presented at the 28<sup>th</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, June 2014.

Croom, LC, Stiles, JS and Emsellem, HA: Non-24-Hour Disorder: A Common Cause of Sleep Complaints in Totally Blind Patients. Presented at the American Association of Nurse Practitioners 28<sup>th</sup> National Conference, June 2013.

Emsellem, HA and Stretz, JE: Decreases in Cataplexy Following the Administration of Sodium Oxybate are Both Time- and Dose Dependent. Presented at the 57<sup>th</sup> Annual Meeting of the American Academy of Neurology, 2005.

Emsellem, HA, Diliberti, JD, Warburton, JS, Croom, LC: Adolescents with Delayed Sleep Phase Syndrome: Characteristics & Treatment Outcome. Presented at the North East Sleep Society annual meeting March 2004.

Emsellem, HA, Harmon, KL and Croom, LC: Thyroid Mass Associated with Tracheal Distortion and Obstructive Sleep Apnea. Presented at the Association of Professional Sleep Societies annual meeting June 2002.

Emsellem, HA and The U.S. Modafinil Study Group: Efficacy and Safety Profiles of Provigil (Modafinil) Maintained during Long-Term (40 and 88 weeks) Treatment of Excessive Daytime Sleepiness Associated with

Narcolepsy. American Academy of Neurology, oral presentation May 2000, San Diego, California.

Dettmann-Quisbert, N, Emsellem, HA and Croom, LC: Treatment of REM-Associated Obstructive Sleep Apnea. Fifth Annual George Washington University Health Sciences Research Day. Competitive, peer-reviewed, poster presentation.

Emsellem, HA et al: Apraxia of Eyelid Opening Associated with Arousal. (Abstract) Sleep Research 25; 1996. Presented June 1996.

Orkin BA, Smith LE, Emsellem HA et al: The Rectal Motor Complex: Propagation at Night. American Society of Colorectal Surgeons. Presented Spring 1992.

Emsellem HA, Rappaport BA, Cooperman DE et al: The Effect of Transcranial Electrical Stimulation on Sleep. Sleep Research 20A: 481, 1991.

Emsellem HA and Jani NN: Narcolepsy in Association with the REM Behavioral Disorder. Sleep Research 20A: 307, 1991.

Lavine BA and Emsellem HA: Attention and Memory During Multiple Sleep Latency Testing (abstract). Sleep Research 20: 125, 1991.

Baldinger DR, Bergsrud DW, Emsellem HA, White PH: The Prognostic Value of Serial SSEP and Radiologic Determinations in Patients with Cervical Spine Inflammatory Arthritis (abstract). 1990 American College of Rheumatology 54<sup>th</sup> Annual Scientific Meeting. Presented, October 1990.

DePalma RG, Schwab FJ, Emsellem HA, Massarin E, Bergsrud DW, Olding MJ: Vascular Interventions for Impotence: Effect of Screening Sequence (abstract). Presented to the 1990 Congress of the International Society for Impotence Research, April 1990.

Lavine B and Emsellem HA: Attention Tasks in Treated and Untreated Narcoleptic Patients. Presented at the meeting of the American Narcolepsy Association, Chicago, April 1990.

Emsellem HA and Rappaport B: An Unusual Artifact vs. Prolonged Periodic Movements of Sleep (abstract). Sleep Research 19: 336, 1990.

Hausfeld JN and Emsellem HA: Development of a Home Screening Test for Sleep Apnea – Clinical Trials and Comparisons. Presented at the 83<sup>rd</sup> Annual Scientific Assembly of the Southern Medical Association, Nov 5, 1989.

Emsellem HA and Rappaport B: Recovery following Prolonged Status

Epilepticus in Thrombotic Thrombocytopenic Purpura (abstract). Presented at the American EEG Society Scientific Meeting, Sept 23, 1989. Publication in Journal of Clinical Neurophysiology, Fall 1989.

Emsellem HA: Narcolepsy in a Patient with Acquired Periodic Alternating Nystagmus (abstract). Sleep Research 18: 229, 1989.

Rothfeld JM, Zeiberg AS, Linebaugh CW, Emsellem HA: An Investigation of Hemispheric Lateralization using Photoc Probe Paradigm (abstract). Society of Neuroscience Abstracts 14 (part 2): 1138, 1988.

Emsellem HA, Bergsrud DW, DePalma RG, Edwards CM: Pudendal Evoked Potentials in the Evaluation of Impotence (abstract). Journal of Clinical Neurophysiology 5(4): 359, 1988.

Smith LE, Curtis D, Emsellem HA, Bergsrud D: Physiologic Techniques for Study of the Anal Sphincter Mechanism and the Pelvic Floor (abstract). Presented at the Section on Colon and Rectal Surgery, Southern Medical Association, 89<sup>th</sup> Annual Scientific Assembly, November, 1987.

Katz LM, Laukaitis J, Emsellem HA, Borenstein D: Evaluation of Cervical Spine Inflammatory Arthritis (CSIA) with Somatosensory Evoked Potentials (SEPs) (abstract). Presented at the American Rheumatism Association, 51<sup>st</sup> Annual Scientific Meeting, June 9 – 13, 1987 – Washington, D.C.

Emsellem HA, Levin J, Pezeshkpour GH, DiMauro S: Familial Myoglobinuria with Tubular Aggregates (abstract). Presented at the Scientific Program, 39<sup>th</sup> Annual Meeting of the American Academy of Neurology – April 7, 1987, New York, New York. Neurology 37(3): 134.

Katz LM, Laukaitis J, Emsellem HA, Borenstein D: Somatosensory Evoked Potentials (SSEP) in the Evaluation of Cervical Spine Inflammatory Arthritis (abstract). Presented at the Southeastern Regional Meeting, American Rheumatism Association – December 1986, White Sulphur Springs, West Virginia. Arthritis and Rheumatism (supplement), January 1987.

DePalma RG, Emsellem, HA, Edwards CM, Drury EM, Schultz SW, Miller HC: A Screening Sequence for Vasculogenic Impotence (abstract). Presented for the Scientific Program, 34<sup>th</sup> Annual Meeting, The North American Chapter of the International Society for Cardiovascular Surgery – June 10, 1986, New Orleans, Louisiana.

## **BOOKS AND CHAPTERS:**

1. Bos, T and Emsellem, HA. Sleep Disorders: Evidence-Based Integrated

- Biopsychosocial Treatment of Insomnia. In Cognitive Behavioral Psychopharmacology: The Clinical Practice of Evidence-Based Biopsychosocial Integration, First Edition. Edited by Mark Dana Muse. John Wiley & Sons Ltd. 2018. Chapter 8, pp 167-192.
2. Pearl, PL and Emsellem, HA. Neuro-Logic – A Primer on Localization. Demos Medical Publishing. 2014.
  3. Emsellem, HA with Whitely, C. Snooze... or Lose! Ten No-War Ways to Improve Your Teen's Sleep Habits. Joseph Henry Press, Washington, D.C. 2006.
  4. Murtagh, KE and Emsellem, HA. Adolescent Sleepiness in Richardson MA & Friedman NR (eds): A Clinician's Guide to Pediatric Sleep Disorders. Informa Healthcare. 2006. Chapter 18, pp 285 – 298.
  5. Emsellem, HA and Murtagh, KE. Sleep Apnea and Sports Performance. Clin Sports Med. 2005 Apr, 24(2): pp 329 – 41.
  6. Emsellem HA: Sleep Disorders in the Elderly. In Yoshikawa, TT, Cobbs E, Brummel-Smith K (eds): Ambulatory Geriatric Care St. Louis, MO, Mosby Year Book, Inc., 1993, Chapter 56, pp 549 – 567.
  7. Emsellem HA, Bergsrud DW: Anal Evoked Potentials. In Smith L (ed): Practical Guide to Anorectal Testing. New York, Igaku-Shoin Medical Publishers, Inc. pp 161 – 166, 1990.
  8. DePalma RG, Schwab FJ, Emsellem HA, Massarian E, Bergsrud D: Noninvasive Assessment of Impotence. In Pearce WH and Yao JST (eds): Surgical Clinics of North America. Philadelphia, WB Co., pp 119 – 132, 1990.
  9. DePalma RG, Emsellem HA, Edwards CM, Druy EM, Schultz SW, Miller HC and Bergsrud D: A screening sequesnce for vasculogenic impotence. In Bergan JJ and Yao JST (eds): The Year Book of Vascular Surgery. Chicago, Year Book Medical Publishers, Inc., pp 96 – 97, 1988.

**COMPETITIVE  
CONFERENCE  
PARTICIPATION:**

January 2011

“Sleep... Why Bother?” 44<sup>th</sup> Annual Winter Conference on Brain Research, Scientific Outreach Program. Summit Middle School. Frisco, CO.

January 2009

“Snooze ... Or Lose!” 42<sup>nd</sup> Annual Winter Conference on Brain Research, Scientific Outreach Program. Cooper Mountain, CO.

January 2007

“Sleep... Why Bother?” 40<sup>th</sup> Annual Winter Conference on Brain Research, Scientific Outreach Program, Summit Middle School. Frisco, CO.

January 2005

“Sleep... Why Bother?” 38<sup>th</sup> Annual Winter Conference on Brain Research, Scientific Outreach Program, Summit Middle School. Frisco, CO.

January 2004

“Sleep... Why Bother?” 37<sup>th</sup> Annual Winter Conference on Brain Research, Scientific Outreach Program, Summit Middle School. Frisco, CO.

January 2002

“Sleep... Why Bother?” 35<sup>th</sup> Annual Winter Conference on Brain Research, Aspen High School. Aspen, CO.

January 2001

“Sleep... Why Bother?” 34<sup>th</sup> Annual Winter Conference on Brain Research, Steamboat Springs High School. Steamboat Springs, CO.

January 2000

“What is Normal for Sleep in Adolescents?” 33<sup>rd</sup> Annual Winter Conference on Brain Research, Summit High School. Frisco, CO.

January 2000

“To Sleep...and Yet to Breathe: A Neuroscientific Exploration of Sleep Apnea” with Kubin, L., Lydic, R., Colrain, I., and Black, J. Panel organizer and participant, 33<sup>rd</sup> Annual Winter Conference on Brain Research, Summit High School. Frisco, CO.

January 1996

“The Neurobiology of Sleep Deprivation” with Everson, C., and Kushida, C. Panel organizer and participant, 29<sup>th</sup> Annual Winter Conference on Brain Research.

January 1993

“Electro-physiological Studies and Sleep Function in Tourette Syndrome” in Workshop: Clinical and Experimental Concepts in Tourette Syndrome” with Hyde, T., Lewitt, PA., Kleinman, JE., and Egan, MF. 26<sup>th</sup> Annual Winter Conference on Brain Research.

January 1990

“Sleep, Dreaming and the Regulation of Brainstem Motor Outflow” with Guillemineault, C., Morrison, A., and Chase, M. Panel Discussion, 23<sup>rd</sup> Annual Winter Conference on Brain Research.

January 1988

“Clinical Syndromes Associated with Diseases Affecting the Non-Cholinergic Basal Forebrain” with Weinberger, D., Kleinman, JN., and Stevens, J.  
Workshop Presentation, 21<sup>st</sup> Annual Winter Conference on Brain Research.

January 1985

“Neuroanatomical Correlates of Confabulation” in Workshop: The Use of Neurologic Illness for Understanding Psychiatric Disorder. 18<sup>th</sup> Annual Winter Conference on Brain Research.

**INVITED  
CONFERENCE  
PARTICIPATION,  
GRAND ROUNDS,  
And LECTURES:**

April 2021

“New Drugs for Sleep and Wakefulness”. Maryland Sleep Society Annual Conference (Virtual).

December 2019

“Positional Obstructive Sleep Apnea”. DC Sleep Society Journal Club, Washington, DC.

October 2019

“Light and Sleep Through the Ages”. Virginia Academy of Sleep Medicine Annual Conference, Richmond, VA.

February 2019

“How to Get a Good Night’s Sleep”. Smithsonian Associates Lecture Series. Washington, DC.

June 2015

“Insights into the Treatment of Narcolepsy”. A CME Dinner Seminar”. Supported by an Independent educational grant from Jazz Pharmaceuticals. Seattle, WA.

September 2014

“Sleep and the Modern Family: Results of the ’14 NSF Poll”. ACSDD Conference. Phoenix, Arizona.

June 2014

“How To Get a Good Night’s Sleep”. Smithsonian Institution’s S. Dillon Ripley Center. Washington, D.C.

October 2013

“Sex and Gender Differences in Sleep: A Roundtable Meeting”. Society for Women’s Health and Research. Washington, D.C.

October 2013

“Review of Sleep in the Adolescent”. The Wake-Kendall Group, PLLC. Washington, D.C.

October 2013

“Resolving Diagnostic Issues and Optimizing Treatment in Narcolepsy: A Case-Based CME Dinner Seminar”. Supported by an Independent educational grant from Jazz Pharmaceuticals. Cleveland, OH.

September 2013

“Sleep Disorders in The Adolescent & Young Adult”. Academy of Clinical Sleep Disorders Disciplines. Scottsdale, AZ.

May 2013

“Sleep for Success”. Smithsonian Institution Lunch & Learn. Washington, D.C.

May 2013

“Non-24-Hour Sleep-Wake Disorder”. Blind Matters Radio Show.

April 2013

“Sleep for Success”. Federal Aviation Administration. Washington, D.C.

March 2013

“Sleep Disorders”.The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

March 2013

“Sleep Disorders and Parkinsons Disease” presented at Ingelside at King Farm. Washington, D.C.

September 2012

“Understanding Sleep: Sleep for Success!” presented at the Department for Health and Human Services. Rockville, MD.

July 2012

“The Basics of Sleeping for Success” presented at Live & Learn Bethesda. Bethesda, MD.

April 2012

“Sleep and Women’s Health: Sleep 101” presented at Society for Women’s Health Research. Washington, D.C.

April 2012

“The Science of Sleep and the Treatment of Sleep Disorders”. Washington, D.C.

March 2012

“Snorts, Gasps and Things that kick and Go Thump in the Night” presented at NIH STEP Sleep Forum. Bethesda, MD.

March 2012

“I’m Not Asleep, But that Doesn’t Mean I’m Awake” presented at NIH STEP Forum. Bethesda, MD.

March 2012

The Mountain Life Show on KPCW Radio. Park City, UT.

January 2012

“Sleep for Success: Teens and Sleep” presented at Georgetown Visitation: Washington Area Independent School Counselors. Washington, D.C.

December 2011

“Understanding Sleep: Sleep for Success!” International Medical Group.

December 2011

“What should Dentists Know About Sleep? The role of the Dentist in the Diagnosis & Management of Sleep Disorders” presented at Anne Arundel County Dental Society. Annapolis, MD.

November 2011

“Sleep for Success: Teens and Sleep” presented at The Academy of the Holy Cross High School. Kensington, MD.

October 2011

“Sleep... Why Bother?” The Academy of the Holy Cross. Kensington, MD.

October 2011

“Teens and Sleep” presented at the Fairfax County Public School, Health Advisory Committee Meeting. Falls Church, VA.

September 2011

“Sleep for Success” presented at the Federal Aviation Association. Washington, D.C.

September 2011

“Parkinson’s and Sleep” presented at the Parkinson Foundation of the National Capital Area. Bethesda, MD.

September 2011

“Sleep for Success” presented at the Holocaust Museum. Washington, D.C.

April 2011

“Evaluation of Sleep Disorders Among College Students” presented at the University of Maryland University Health Center. College Park, MD.

March 2011

“GOT SLEEP? Overview of Sleep and the Role of the Dentist in the Diagnosis and Treatment of Sleep Disorders” presented at the District of Columbia Dental Society’s 79<sup>th</sup> Annual Nation’s Capital Dental Meeting. Washington, D.C.

March 2011

“Sleep in the Adolescent” presented at the National Sleep Foundation’s Sleep Health and Safety 2011 Conference. Washington, D.C.

February 2011

“Sleep... Why Bother??” presented at the All School Conference. Glens Falls High School, NY.

February 2011

“The Science of Adolescent Sleep & the Treatment of Teen Sleep Disorders” presented at Grand Rounds. Glens Fall Hospital, NY.

February 2011

“Sleep! For Student Success: The Science of Adolescent Sleep” presented for the Glens Fall School System PTA. Glens Falls, NY.

January 2011

“Sleep... Why Bother??” presented at the Summit High School to the International Baccalaureate class. Breckenridge, CO.

January 2011

“The Science of Sleep: How to Sleep for Success” presented at the Community Outreach for the Winter Conference on Brain Research. Keystone, CO.

October 2010

“Comprehensive Management of Narcolepsy in Teens” presented at the 2010 Narcolepsy Network Conference. Arlington, VA.

October 2010

“The Science of Adolescent Sleep and the Treatment of Teen Sleep Disorders” presented at the Virginia Academy of Sleep Medicine Annual Conference. Richmond, VA.

April 2010

“Lessons of Sleep” presented on The Diane Rehm Show.NPR, Washington, D.C.

April 2010

“Sleep... Why Bother??” presented to high school students and administration. Westminster School, Hartford, CT.

March 2010

“Gait Disorders” and “Sleep Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

July 2009

“Sleep Requirements for Adolescents”.A sleep education curriculum summary at the Health and Physical Education Summer Leadership Program for Montgomery County Public School Teachers. Rockville, MD.

June 2009

“What’s Your Specialty” presented to high school students sponsored by National Youth Leadership Forum on Medicine. Washington, D.C.

April 2009

“Snooze... or Lose! Sleep Purpose and Needs of Adolescents” presented to high school students. The Bullis School, Potomac, MD.

March 2009

“Gait Disorders” and “Sleep Disorders”.The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

December 2008

“Sleepy, Sleep-Deprived Teens” presented to high school students. Flint Hill High School, Oakton, VA.

April 2008

“Gait Disorders”, “Sleep Disorders: Overview”, and “Sleep Disorders: Case Studies”. Des Moines University School of Osteopathic Medicine lectures. Des Moines, IA.

March 2008

“Gait Disorders” and “Sleep Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

November 2007

“Awake and Not Happy About It”.A presentation for the Parkinson Foundation of the National Capital Area. Chevy Chase, MD

July 2007

“Snooze... or Lose!” sermon presented to B’nai Israel Congregation.  
Rockville, MD.

June 2007

“Neurology & Sleep Medicine as Careers” presented to high school students sponsored by the National Youth Leadership Forum on Medicine. Washington, D.C.

March 2007

The George Washington University School of Medicine and Health Sciences, Physical Diagnosis Teaching Session. Washington, D.C.

March 2007

“Gait Disorders” and “Sleep Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

December 2006

“Parkinson’s Disease and Sleep Disorders”. A presentation for the Parkinson Foundation of the National Capital Area.

October 2006

“Sleep Disorders and ADHD”. A presentation for CHADD of Northern Virginia. Vienna, VA.

July 2006

Cephalon Pediatric Sleep Data Review Meeting, Investigator Panel Member. Washington, D.C.

June 2006

“Sleep Disorders in Psychiatric Practice”. A roundtable discussion through the SCN Network. Bethesda, MD.

May 2006

“Sleep Disorders in Psychiatry and Internal Medicine” presented through the SCN Network. Bethesda, MD

May 2006

“Sleep... Why Bother??” presented at the Diplomatic Health Fair. French Embassy, Washington, D.C.

April 2006

“Sleepy, Sleep-Deprived Teens” presented to high school students and parents. Sandy Spring Friends School, Sandy Spring, VA.

February 2006

“Sleep, Sleep-Deprived Teens” presented to high school students and parents. McLean High School, McLean, VA.

November 2005

“Psychiatric Issues in the Pediatric Primary Care Setting” presented on Adolescent Sleep Disorders. CME lectures, Fairfax, VA.

September 2005

“Sleep Disorders in Psychiatric Practice” presented at the Washington Psychiatric Society’s annual symposium. Washington, D.C.

May 2005

“Sleep Disorders in Children and Adolescents” dinner lecture for pediatricians, pediatric neurologists, and pediatric psychologists, sponsored by Cephalon. Washington, D.C.

March 2005

Medical Grand Rounds Holy Cross Hospital. Management of Sleep Disorders. Silver Spring, MD.

March 2005

“Gait Disorders” and “Sleep Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

October 2004

“Neurochemical Mechanisms of Alertness”. National Faculty Meeting, Health Science Center for Continuing Medical Education. Seattle, WA.

October 2004

“Awake & Involved II: Addressing Excessive Daytime Sleepiness and Fatigue in Neurologic Disorders”. Projects in Knowledge. Vienna, VA.

September 2004

Editor of CME-certified newsletter: Update from June National Sleep Meeting: Focus on the Treatment of disorders of Excessive Daytime Sleepiness. Health Science Center for Continuing Medical Education.

September 2004

“Evaluation and Management of Excessive Daytime Sleepiness”. Health Science Center for Continuing Medical Education. Washington, D.C.

June 2004

Faculty Member for an Educational Symposium: New Data and Emerging

Trends in the Treatment of Excessive Daytime Sleepiness. Philadelphia, PA.

June 2004

“Diagnosis and Initial Treatment of Narcolepsy”. Meet the Professor Session, Associated Professional Sleep Societies Annual Meeting. Philadelphia, PA.

April 2004

“Sleep Disorders and ADD”.Northern Virginia Psychiatric Study Group. Oakton, VA.

April 2004

“Current Issues in the Management of Disorders of Sleep and Wakefulness”.Cogenix.Loudoun Hospital Center, Leesburg, VA.

March 2004

“Gait Disorders” and “Sleep Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

February 2004

Editor: Evaluation and Management of Excessive Daytime Sleepiness Slide Kit. Health Science Center for Continuing Medical Education.

December 2003

“The New Epidemic Facing Women: Lack of Sleep”. The Center for Association Leadership, Women Executives Forum. Washington, D.C.

July 2003

“Awake & Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson’s Disease”. Bethesda, MD.

June 2003

“Diagnosis and Initial Treatment of Narcolepsy”. Meet the Professor Session, Associated Professional Sleep Societies Annual Meeting. Chicago, IL.

September 2002

“Sleepless in Washington: The Pharmacological Engineering of Human Needs”. Program of Dialogue on Science, Ethics, and Religion for the American Association for Advancement of Science. Washington, D.C.

June 2002

“Sodium Oxybate Clinical Updates”. Associated Professional Sleep Societies Annual Meeting. Seattle, WA.

June 2002

“Sleep Disorders and Sleep Apnea”.Academy of Family Physicians Annual

Assembly 2002. Ocean City, MD.

April 2002

“GHB & Modafinil – Treatment for Narcolepsy”. Northeast Sleep Society 16<sup>th</sup> Annual Meeting on REM Sleep: From Physiology to Dreaming. Baltimore, MD.

April 2002

“Politics of GHB”. Southern Sleep Society 24<sup>th</sup> Annual Meeting. Bethesda, MD.

March 2002

“Gait Disorders”. The George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

November 2001

“Sleep, Stress and Shift Work”. IntelSat. Washington, D.C.

November 2001

“Sleep, Why Bother?” Columbia Union College. Academic Dean’s Lecture Series. Takoma Park, MD.

October 2001

“Headaches and Sleep Disorders”. Sponsored by Pharmacia & Upjohn Co. Bethesda, MD.

October 2001

“New Treatments for Narcolepsy”. Sleep Across the Ages Conference. Chesapeake Bay Sleep Society. Baltimore, MD.

March 2001

“Women and Sleep Disorders”. Fairfax County Medical Society. Fairfax, VA.

April 2001

“Doctor, I Can’t Sleep: ... ‘Sleep-Wrecked’ in America”. Internal Medicine Clinical Review, Suburban Hospital. Bethesda, MD.

February 2001

“Insomnia: Diagnosis and Treatment”. Sponsored by Wyeth-Ayerst Pharmaceuticals. Wheaton, MD.

November 2000

“Physiology of Sleep in Adolescents”. Focus Group on Adolescent Sleep. Bethesda/Chevy Chase High School/Montgomery County Schools/National Sleep Foundation.

May 2000

“The Effects of Provigil on Quality of Life in Patients with Narcolepsy”.Sponsored by Cephalon, Inc. Chevy Chase, MD.

April 2000

“Sleep and Adolescents”.Whitman Community Youth Summit 2000, Walt Whitman High School. Bethesda, MD.

February 2000

“The Treatment and Management of Narcolepsy”.Sponsored by Cephalon, Inc. Bethesda, MD.

January 2000

“The Effects of Provigil on Quality of Life in Patients with Narcolepsy”.Sponsored by Cephalon, Inc. West Palm Beach, FL.

December 1999

“The Current Treatment and Management of Insomnia”.Grand Rounds, Department of Medicine, Montgomery General Hospital. Olney, MD.

December 1999

“The Current Treatment and Management of Insomnia”.Sponsored by Searle Pharmaceuticals. Bethesda, MD.

December 1999

“The Current Treatment and Management of Insomnia”.Sponsored by Searle Pharmaceuticals. Washington, D.C.

November 1999

“The Treatment and Management of Narcolepsy”.Sponsored by Cephalon Pharmaceuticals.Chevy Chase, MD.

October 1999

“Excessive Daytime Sleepiness – Is It Narcolepsy?” Sponsored by Cephalon Pharmaceuticals. Vienna, VA.

October 1999

“The Current Treatment and Management of Insomnia”.Psychiatry Grand Rounds.Ritz Carlton, Washington D.C.

September 1999

“The Current Diagnosis and Management of Obstructive Sleep Apnea”.Grand Rounds, Department of Medicine, Sibley Memorial Hospital. Washington, D.C.

June 1999

“The Current Treatment and Management of Insomnia”.Grand Rounds,Department of Medicine, Holy Cross Hospital. Silver Spring, MD.

June 1999

“The Current Diagnosis and Management of Obstructive Sleep Apnea”.Grand Rounds, Department of Medicine, Washington Hospital Center. Washington, D.C.

April 1999

“A New Dawn for Patients with Narcolepsy: Promoting Daytime Alertness”. Sponsored by Projects in Knowledge, Inc.Audioconference Series.

March 1999

“The Diagnosis and Current Management of Narcolepsy”.Neurology Grand Rounds, Howard University Medical Center. Washington, D.C.

February 1999

“The Diagnosis and Current Management of Narcolepsy”.Grand Rounds, Department of Neurology, Fairfax Hospital. Fairfax, VA.

February 1999

“Abuse Potential of Narcolepsy Treatments”.Sponsored by Cephalon Pharmaceuticals.

December 1998

“Sleep Scenarios”.Grand Rounds,Department of Medicine, Suburban Hospital. Bethesda, MD.

October 1998

“Sleep Disorders in Students”.Student Health, University of Maryland. College Park, MD.

July 1998

“Sleep Disorders”.George Washington University Psychiatry Board Review for Neurologists. Arlington, VA.

July 1998

“Psychiatric Aspects of Sleep Disorders”.George Washington University Psychiatry Board Review course. Arlington, VA.

July 1998

“The Current Treatment and Management of Insomnia”.Department of Medicine, Suburban Hospital. Bethesda, MD.

July 1998

“Sleep Disorders”.Invited Guest, Washington D.C. Psychiatric Board Review Course.Washington, D.C.

June 1998

“Psychopharmacologic Agents and Sleep”.Invited Guest, Washington D.C.  
Psychiatric Study Group.Washington, D.C.

June 1998

Modafinil Advisory Panel and Marketing Consultant Meetings. New Orleans,  
LA.

April 1998

“Sleep Disorders in the Elderly”. Guest Speaker, American Geriatric  
Society/Metropolitan Washington, D.C. Area Affiliate Quarterly Meeting.  
Washington, D.C.

April 1998

“Clinical Efficacy and Safety of Modafinil in the Management of Narcolepsy”  
(Lecture) and “Modafinil and its Place in the Management of Narcolepsy”  
(Panel Discussant).State of the Art in the Management of Sleep Disorders.  
Annecy, France.

February 1998

“New Insights in the Management of Narcolepsy: Perspectives in Neurology”.  
Neurology Grand Rounds, University of South Carolina.Charleston, SC.

December 1997

Modafinil Advisory/Consultants Workshop, Workshop Session Leader. Ponte  
Vedra, FL.

December 1997

“New Headache Treatment Strategies”.Grand Rounds, Suburban Hospital.  
Bethesda, MD.

November 1997

“Shift Work and Sleep Disorders”.IntelSat. Washington, D.C.

October 1997

“Diagnosis and Treatment of Sleep Disorders and Depression”. Medical  
Education Program, sponsored by Pfizer Pharmaceuticals.

August 1997

“Approach to the Patient with Sleep Related Complaint”. Internal Medicine  
Clinical Review, Suburban Hospital. Bethesda, MD.

June 1997

CephalonModafinil Abuse Liability discussions and meetings.Philadelphia,  
Pennsylvania.

January 1997

“Modafinil Abuse Liability”.Presentation, Provigil Marketing Advisory Board Meeting.Tuscon, AZ.

December 1996

“Sleep Disorders in the Elderly”.Raphael House Presentation. Rockville, MD.

November 1996

Physician Facilitator, Provigil Marketing Advisory Board Meeting. Chicago, IL.

September 1996

Presentation of 301/302 Protocol Data on the Use of Modafinil in the Treatment of Narcolepsy to the United Kingdom, National Health Service. Nottingham, England.

July 1996

“Seizure Disorders” and “Sleep Disorders”.George Washington University Psychiatry Board Review course. Arlington, VA.

July 1996

“Seizures and Stroke”.Montgomery County Maryland Stroke Club.

July 1996

“Narcolepsy Management”.Bimonthly Sleep Expert Meeting, Greater Washington Sleep Center.

June 1996

“Overview of Sleep Disorders”.Grand Rounds, Humana. Suitland, MD.

May 1996

“Overview of Sleep Disorders and Insomnia”.Grand Rounds, Kaiser Permanente. Falls Church, VA.

April 1996

“Overview of Insomnia”.Postgraduate Education Program, Young Physicians of the DC Medical Society.Washington, D.C.

March 1996

“The Diagnosis and Management of Insomnia”.Grand Rounds, Kaiser Permanente. Woodbridge, VA.

February 1996

“The Diagnosis and Management of Insomnia”.Lecture, Kaiser Permanente. Springfield, VA.

February 1996

“The Diagnosis and Management of Insomnia”.Grand Rounds, Kaiser Permanente. Reston, VA.

January 1996

“Overview of Sleep Disorders”.Grand rounds, Physicians Memorial Hospital. La Plata, MD.

January 1996

“The Diagnosis and Management of Insomnia”. North Capitol Lecture, Kaiser Permanente. Washington, D.C.

November 1995

“Overview of Sleep Disorders”.Grand Rounds, Harford Memorial Hospital. Havre De Grace, MD

November 1995

“Overview of Sleep Disorders”.Grand Rounds, Kaiser Permanente. Kensington, MD.

September 1995

“The Role of Sleep in Fibromyalgia”. Lecture Presentation and Group Discussion, Fibromyalgia Foundation Seminar.

September 1995

CPC Presentation – Discussion of an unknown case (polio). Medical Grand Rounds, Suburban Hospital. Bethesda, MD.

August 1995

“Multiple Sclerosis: An Ever-Changing Problem in Diagnosis and Management”. Medical Grand Rounds, Suburban Hospital. Bethesda, MD.

July 1995

“Dementia and Aging”, “Demyelinating Disease”, and “Stroke”.American College of Physicians Internal Medicine Board Review. Washington, D.C.

April 1995

“Gait Disorders”. George Washington University Department of Neurology Introduction to Clinical Medicine course. Washington, D.C.

March 1995

“Evaluation of the Patient with Insomnia”.Grand Rounds, Kaiser Permanente. Woodbridge, VA.

November 1994

“Overview of Sleep Disorders”. Lecture to Prince George’s County Medical Society General Membership Meeting. Greenbelt, MD.

July 1994

“Dementia and Aging”, “Demyelinating Disease”, and “Stroke”. American College of Physicians Internal Medicine Board Review. Washington, D.C.

June 1994

“Treatment of Sleep Disorders”. Grand Rounds, Potomac Ridge Psychiatric Treatment Center. Rockville, MD.

May 1994

“Professional Development for Women Neurologists”. Panel Discussion Participant, Women in Neurology Section. Academy of Neurology. Washington, D.C.

February 1994

“Insomnia”. Grand Rounds, Department of Medicine, Bethesda Naval Hospital. Bethesda, MD.

January 1994

“Doctor, I Can’t Sleep”. Grand Rounds, Department of Medicine, Holy Cross Hospital. Silver Spring, MD.

November 1993

“Neurological Case Studies”. Grand Rounds, Neuroscience Center of the National Institute of Health. Bethesda, MD.

October 1993

“Doctor, I Just Can’t Get a Good Night’s Sleep”. Grand Rounds, Department of Medicine, Suburban Hospital. Bethesda, MD.

September 1993

“The Diagnosis and Management of Obstructive Sleep Apnea”. Department of Medicine Grand Rounds, Sibley Memorial Hospital. Washington, D.C.

September 1992

“Dementia and Aging”, “Demyelinating Disease”, and “Stroke”. American College of Physicians Internal Medicine Board Review. Washington, D.C.

August 1992

“The Neurology of the Saddle”. Department of Medicine, Suburban Hospital. Bethesda, MD.

August 1992

“Sleep Disorders and the Use of the Sleep Laboratory”. Dominion Hospital. Falls Church, VA.

May 1992

“Indication for Sleep Studies and Polysomnography”.Grand Rounds, Neuroscience Center of the National Institute of Mental Health.Bethesda, MD.

May 1992

“New Developments in the Management of Neurological Disorders”.American College of Physicians Internal Medicine Board Review. Washington, D.C.

January 1992

“Management of Cerebrovascular Symptomatology from a Cardiac Perspective”. Cardiology Grand Rounds, The George Washington University Department of Medicine. Washington, D.C.

January 1992

“Neurology”.American College of Physicians MKSAP IX Board Review course.

January 1992

“Sleep Disorders ... the Great Mimicker”.CNS Grand Rounds, Dominion Hospital.Falls Church, VA.

September 1991

“Special Seminar: Headache Management”. American Academy of Family Physicians 43<sup>rd</sup> Annual Assembly.

July 1991

“Cerebrovascular Disease”, “Demyelinating Disease”, and “Dementia & Seizures”.American College of Physicians Internal Medicine Board Review Course. Washington, D.C.

May 1991

“Sleep Disorders and Sleep Studies”. Grand Rounds, Department of Health Care Sciences, The George Washington University. Washington, D.C.

February 1991

“Electrophysiology Case Conference”. Grand Rounds, Department of Neurology, The George Washington University. Washington, D.C.

February 1991

“Current Concepts in the Management of Demyelinating Disease”. Grand Rounds, AMI Doctors’ Hospital. Lanham, MD.

January 1991

“To Sleep...” Grand Rounds, Department of Medicine, The George Washington University. Washington, D.C.

December 1990

“Multiple Sclerosis Update”. Noon Conference, Department of Medicine, The George Washington University. Washington, D.C.

September 1990

Testimony as Expert Witness at the Congressional Hearing for the National Commission on Sleep Disorders Research. Washington, D.C.

July 1990

“Anal Evoked Potentials”. Third Congress on the Laboratory Study of the Anus, Rectum, and Colon.

July 1990

“Demyelinating Diseases”, “Seizures and Sleep Disorders”, and “Cerebrovascular Disease”. American College of Physicians Internal Medicine Board Review. Washington, D.C.

April 1990

“Neurology”. American College of Physicians MKSAP VIII Review Course. Washington, D.C.

November 1989

“Seizures While on Neuroleptic Medication”. National Institute of Mental Health Clinical Brain Disorders Branch Clinical Case Conference. Neuroscience Research Center of the National Institute of Health. Washington, D.C.

October 1989

“The Diagnosis and Management of Metastatic Disease of the Spine, Plexi, and Base of the Skull”. Medical Oncology Board Review Course. Washington, D.C.

September 1989

“Neurology”. American College of Physicians MKSAP VIII Review Course. Washington, D.C.

September 1989

“Portable Apnea Screening Tests”. Otolaryngology Grand Rounds, Sibley Hospital. Washington, D.C.

May 1989

“EEGs and Non-invasive Neurologic Testing”. Grand Rounds, Department of Health Care Sciences, The George Washington University. Washington, D.C.

February 1989

“Sleep Disturbance in Patients with Musculoskeletal Pain Syndromes”. Rheumatology Section Grand Rounds, Fairfax Hospital. Falls Church, VA.

January 1989

“Sleep Disorders in Adolescents”. Adolescent Medicine Grand Rounds, Children’s Hospital National Medical Center. Washington, D.C.

September 1988

“Evaluation and Treatment of Sleep Disorders”. Grand Rounds, AMI Doctors’ Hospital. Maryland.

August 1988

“CPC – Wallenberg Syndrome”. Grand Rounds, Department of Medicine, The George Washington University. Washington, D.C.

July 1988

“Evoked Potentials of Pudendal Nerves”. Second Congress on the Laboratory Study of the Anus, Rectum, and Colon. Washington, D.C.

May 1988

“Mark Twain Neurology”. Panel Presentation, Grand Rounds, Department of Medicine, Washington Hospital Center. Washington, D.C.

May 1988

“Diagnosis and Treatment of Common Neurological Disorders” and “Case Studies”. Update in Internal Medicine. Department of Medicine, The George Washington University Medical Center. Washington, D.C.

March 1988

“Sleep Disorders in the Elderly”. Jewish Community Center of Greater Washington. Washington, D.C.

February 1988

“Electroencephalography and Evoked Potentials”. The George Washington University Neurosurgical Board Review Conference. Washington, D.C.

December 1987

“Multidisciplinary Perspectives to Answer Your Patient Related Problems About Sleep Disorders” and “Portable Monitoring for Obstructive Sleep Apnea”. Medlantic Institute Conference: Sleep Problems and Solutions, 1987.

November 1987

“Sleep Disorders in the Elderly”. Northern Virginia Jewish Community Center. Fairfax, VA.

October 1987

“Neuro-oncology”. The George Washington University Board Review Course in Medical Oncology. Washington, D.C.

June 1987

“Diagnosis and Treatment of Common Neurological Disorders” and “Case Studies”. Update in Internal Medicine, Department of Medicine, The George Washington University Medical Center. Washington, D.C.

March 1987

“Neurology Section”. American College of Physicians MKSAP VII Review Course. Washington, D.C.

March 1987

“Pudendal Nerve Studies”. Colo-Rectal Surgery Conference, Division of Colo-Rectal Surgery, The George Washington University Hospital. Washington, D.C.

March 1987

“Sleep and the Elderly”. Winter/Spring 1987 Geriatric Meeting, Division of Geriatric Medicine, The George Washington University. Washington, D.C.

October 1986

“A Young Man with Rapidly Progressive Paralysis”. Grand Rounds, CPC, Department of Medicine, The George Washington University Hospital. Washington, D.C.

October 1986

“Medical Aspects of Rehabilitation: Functional Limitations of Epilepsy”. The George Washington University Regional Rehabilitation Continuing Education Program. Washington, D.C.

June 1986

“Diagnosis and Treatment of Common Neurological Disorders” and “Case Studies”. Internal Medicine Review Board, Department of Medicine, The George Washington University. Washington, D.C.

October 1985

“Neuro-oncology”. The George Washington University Board Review Course in Medical Oncology. Washington, D.C.

September 1985

“Emergency Neurology: Pitfalls and Pearls in Diagnosis and Management” and “Headache, Syncope, and Dizziness: The Emergency Physician’s Dilemma”. American College of Emergency Physicians Scientific Assembly. Las Vegas, NV.

September 1985

“Evoked Potentials in Rheumatoid Arthritis”. Grand Rounds, Division of Rheumatology, The George Washington University. Washington, D.C.

August 1985

“Creative Neurophysiology: EEG, Evoked Potentials and Color Glossy Brain Mapping”. Grand Rounds, Department of Medicine, The George Washington University.

May 1985

“Diagnosis and Treatment of Common Neurological Disorders” and “Case Studies”. Update in Internal Medicine, Department of Medicine, The George Washington University Medical Center. Washington, D.C.

April 1985

“Cerebral Cysticercosis”, “The Patient with Third Nerve Palsy”, and “The Patient with CaudaEquina Tumor”. Pitfalls and Pearls Conference. Washington, D.C.

October 1984

“Multiple Sclerosis”. The George Washington University Regional Rehabilitation Continuing Education Program. Washington, D.C.

September 1984

“Vertigo” and “Headache Management”. The George Washington University Primary Care Update CME Conference. Washington, D.C.

June 1984

“Headache: A Practical Approach”. Grand Rounds, Department of Health Care Sciences, The George Washington University. Washington, D.C.

May 1984

“Headache in the ER: Selected Case Studies” and “Case Studies in Neurologic Emergencies”. Pitfalls and Pearls Conference. Washington, D.C.

February 1984

“Metastatic Spinal Cord Disease”. The George Washington University Multidisciplinary Cancer Teaching Conference. Washington, D.C.

February 1984

“Diagnosis and Treatment of Common Neurological Disorders” and “Case Histories in Neurology”. Update in Internal Medicine, Department of Medicine, The George Washington University Medical Center. Washington, D.C.

February 1984

“Epilepsy”. The George Washington University Regional Rehabilitation Continuing Education Program. Washington, D.C.

December 1983

“Acquired Immune Deficiency Syndrome”. Grand Rounds, CPC, Department of Medicine, The George Washington University. Washington, D.C.

November 1983

“The Emergency Room Evaluation of Headache”. Grand Rounds, Department of Emergency Medicine, The George Washington University. Washington, D.C.

September 1983

“Vertigo”.Grand Rounds, Suburban Hospital. Bethesda, MD.

April 1983

“Spinal Cord Syndromes” and “Acute Diplopia: Serious or Trivial”.Pitfalls and Pearls Conference. Washington, D.C.

March 1983

“Diagnosis and Treatment of Common Neurological Disorders”. Update in Internal Medicine, Department of Medicine, The George Washington University Medical Center. Washington, D.C.

July 1982

“Case Histories in Neurology”. Update in Internal Medicine, Department of Medicine, The George Washington University Medical Center. Washington, D.C.

June 1982

“Multiple Sclerosis”. Grand Rounds, Department of Health Care Sciences, The George Washington University. Washington, D.C.

May 1982

“Emergency Room Evaluation of the Vertiginous Patient”.Pitfalls and Pearls Conference. Washington, D.C.

**SPEAKERS**

**BUREAU:**

2019 - 2021  
Harmony Biosciences

**CONSULTANT:**

November 2010  
Neupro Pharmaceuticals Advisory Board Meeting. Cambridge, MA.

November 2005  
Jazz Pharmaceuticals Advisory Board Meeting.

April 2005  
Examiner for the American Board of Psychiatry, Part II Examinations of the American Board of Psychiatry and Neurology. Washington, D.C.

May 2002

Examiner for the American Board of Psychiatry, Part II Examinations of the American Board of Psychiatry and Neurology. New York, NY.

1998

Guest Member, Committee to Evaluate the Effect of School Start Times on Adolescents, Montgomery Board of Education. Rockville, MD

**ADVISORY BOARD:**

2018

Harmony Biosciences Commercial Advisory Board

2012 - 2016

Vanda Pharmaceuticals Non-24 Hour Sleep-Wake Disorders “Non” 24 Advisory Board

2012

Jazz Pharmaceuticals “Best Practices in Narcolepsy Management” Advisory Board Meeting

2009

National Sleep Foundation Public Awareness Committee

2005

National Sleep Foundation Advisory Board for Adolescent Sleep Initiative

2005

National Sleep Foundation Panel for Bath & Body Works, Inc.

1999

Montgomery County Bell Times Committee: To change school start times

**REVIEWS:**

2001

Review for the Department of Veterans Affairs Grant Committee of the Merit Review Application: “Clinical Outcomes of CPAP Therapy in OSA: Alertness, Memory, and Affect” submitted by Max Hirshkowitz of Houston, TX.

2000

Specialist Reviewer for the Peer Review Management Committee of the Board of Physician Quality Assurance (BPQA). Med Chi, The Maryland State Medical Society.